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Introduction {#jdi13208-sec-0005}
============

Diabetic nephropathy (DN) is a well‐known microvascular complication of diabetes mellitus, and currently the primary cause of chronic kidney disease and end‐stage renal disease (ESRD) globally[1](#jdi13208-bib-0001){ref-type="ref"}. DN is a syndrome characterized by the gradual loss of kidney function with pathological quantities of urine albumin excretion. For the timely intervention against DN, it is quite important to detect the increased urine albumin excretion as soon as possible. Epidemiological studies have shown that the prevalence rates of albuminuria range 19.5--49% among patients with type 2 diabetes mellitus[2](#jdi13208-bib-0002){ref-type="ref"}, [3](#jdi13208-bib-0003){ref-type="ref"}, [4](#jdi13208-bib-0004){ref-type="ref"}. Aging, sex, hypertension, hyperglycemia, abnormal lipid profile, smoking, insulin resistance and metabolic syndrome have been reported to be the risk factors for albuminuria[2](#jdi13208-bib-0002){ref-type="ref"}. In addition, increasing evidence shows that genetic factors play an important role in the development of DN[5](#jdi13208-bib-0005){ref-type="ref"}.

Peroxisome proliferator‐activated receptor gamma (*PPAR‐γ*), a ligand‐activated transcription factor, is a response for the regulation of numerous biological processes, such as cell proliferation, adipocyte cell differentiation and inflammation. Thiazolidinediones serve as *PPAR‐γ* agonists, and improve blood sugar control in type 2 diabetes mellitus patients through the enhancement of insulin sensitivity[6](#jdi13208-bib-0006){ref-type="ref"}. Furthermore, *PPAR‐γ* agonists ameliorate metabolic abnormalities of diabetes and consecutive DN[7](#jdi13208-bib-0007){ref-type="ref"}. The Pro12Ala polymorphism is the most frequent variation in the PPARγ gene and accounts for 4--14% of the population[8](#jdi13208-bib-0008){ref-type="ref"}, [9](#jdi13208-bib-0009){ref-type="ref"}, [10](#jdi13208-bib-0010){ref-type="ref"}, [11](#jdi13208-bib-0011){ref-type="ref"}, [12](#jdi13208-bib-0012){ref-type="ref"}, [13](#jdi13208-bib-0013){ref-type="ref"}, [14](#jdi13208-bib-0014){ref-type="ref"}. The Pro12Ala polymorphism is related to reducing the deoxyribonucleic acid (DNA) binding affinity and diminishing the transcriptional activity *in vitro* [15](#jdi13208-bib-0015){ref-type="ref"}. Furthermore, individuals who carried the *Ala* allele had significant elevation in insulin sensitivity[15](#jdi13208-bib-0015){ref-type="ref"}, which might be a protective factor for DN[9](#jdi13208-bib-0009){ref-type="ref"}, [10](#jdi13208-bib-0010){ref-type="ref"}, [13](#jdi13208-bib-0013){ref-type="ref"}, [14](#jdi13208-bib-0014){ref-type="ref"}, [16](#jdi13208-bib-0016){ref-type="ref"}, [17](#jdi13208-bib-0017){ref-type="ref"}, [18](#jdi13208-bib-0018){ref-type="ref"}, [19](#jdi13208-bib-0019){ref-type="ref"}.

Some studies supported that the *PPAR‐γ*Pro12Ala polymorphism might contribute to reducing the risk of DN in type 2 diabetes mellitus patients[9](#jdi13208-bib-0009){ref-type="ref"}, [10](#jdi13208-bib-0010){ref-type="ref"}, [13](#jdi13208-bib-0013){ref-type="ref"}, [14](#jdi13208-bib-0014){ref-type="ref"}, [16](#jdi13208-bib-0016){ref-type="ref"}, [17](#jdi13208-bib-0017){ref-type="ref"}, [18](#jdi13208-bib-0018){ref-type="ref"}, [19](#jdi13208-bib-0019){ref-type="ref"}, but some other studies suggested there was no significant association[8](#jdi13208-bib-0008){ref-type="ref"}, [20](#jdi13208-bib-0020){ref-type="ref"}, thus leaving uncertainty about its role in diabetic renal disease. To further understand this issue, we carried out a case--control study with type 2 diabetes mellitus patients of ethnic Chinese backgrounds in southern Taiwan to test the association between *PPAR‐γ*Pro12Ala polymorphism and albuminuria.

Methods {#jdi13208-sec-0006}
=======

Patients with type 2 diabetes mellitus (*n* = 581) followed up at least 1 year before enrollment were recruited from the outpatient clinic at Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, between January 2017 and October 2017. After excluding 27 patients with anuria or oliguria due to ESRD under regular hemodialysis, a total of 554 participants were analyzed, and participants were divided into normoalbuminuria and albuminuria groups in October 2017 according to the following definition. Albuminuria was evaluated on the basis of the urine albumin‐to‐creatinine ratio (UACR) obtained from the initial voiding of urine in the morning. Normoalbuminuria (NA) was defined as a UACR \<30 mg/g of the last two of three urine samples. Microalbuminuria (MA) was defined as an UACR of ≥30 and \<300 mg/g, and macroalbuminuria (MAA) was defined as an UACR ≥300 mg/g in at least two urine samples in the past 3‐ to 6‐month period[21](#jdi13208-bib-0021){ref-type="ref"}. Albuminuria was defined as the presence of MA or MAA. Diabetic retinopathy was evaluated through annual fundus photography by experienced diabetes doctors, and would be referred to ophthalmologists for abnormal findings.

All of the study participants received a standardized clinical and laboratory evaluation according to the standard clinical practice of our institution and recommendations from the Diabetes Association of Republic of China, Taiwan[22](#jdi13208-bib-0022){ref-type="ref"}. Information about alcohol use and smoking habits was obtained using questionnaires. Smoking habits are defined as positive for current smokers regardless of how much they smoked. Alcohol use was defined as positive for more than one drink per day for women and two drinks per day for men. Information regarding the use of antihypertensive medications, lipid‐lowering agents, oral blood glucose‐lowering agents and insulin treatments was collected from the electronic medical record systems at the hospital. Individuals were considered to have diabetes mellitus if they were taking diabetes medications or showed a hemoglobin A1c of ≥6.5% on repeated testing[23](#jdi13208-bib-0023){ref-type="ref"}. Hypertension was defined as either receiving antihypertensive medications or systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg[24](#jdi13208-bib-0024){ref-type="ref"}. The study protocol was approved by the Human Research Ethics Committee at our hospital, and all participants were given written‐form informed consent.

Genotyping {#jdi13208-sec-0007}
----------

Each participant's genomic DNA was extracted from leukocytes in peripheral blood samples. The *Pro12Ala* gene polymorphism was analyzed by real‐time polymerase chain reaction (PCR). The single‐nucleotide polymorphism (SNP) genotyping assays, also known as TaqMan assay, used to detect specific polymorphisms were purchased from Topgen Biotechnology (Kaohsiung City, Taiwan). SNP genotyping assays use TaqMan 5′‐nuclease chemistry for amplifying and detecting specific polymorphisms in purified genomic DNA samples. All probes for quantitative PCR assays were 5′ labeled with FAM/VIC as a reporter and 3′ labeled with minor groove binder non fluorescent quencher as a quencher. A total of 20 ng of DNA was amplified using the TaqMan SNP assay. Preparation of quantitative PCR reaction followed the manufacturer's instructions (Topgen Biotechnology). The cycling parameters were as follows: (i) 5 min at 95°C; (ii) 30 s at 60°C; (iii) 40 cycles at 95°C for 3 s and then 60°C for 40 s; and (iv) 30 s at 60°C. Real‐time PCR was carried out using 2X AceQ Probe High ROX qPCR Master Mix (Topgen Biotechnology) on StepOne Plus Real Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Allelic discrimination was called by StepOne software v2.3 (Applied Biosystems, Grand Island, NY, USA).

Statistical analysis {#jdi13208-sec-0008}
--------------------

Patients' clinical and biochemical characteristics were presented as the mean ± standard deviation or percentages. The values of triglyceride, UACR, creatinine and estimated glomerular filtration rate (eGFR) were natural log‐transformed due to the non‐normal distribution. Data analysis was carried out using the statistical package for social sciences (SPSS) 25 software (IBM Corporation, Armonk, NY, USA). Statistical significance of the differences between the groups was determined by χ^2^‐tests for categorical variables, and unpaired Student's *t*‐test for continuous variables. Binary logistic regression was used to describe the associations of variables with the presence of albuminuria controlling for potential confounders. In all statistical tests, *P* \< 0.05 was considered statistically significant.

Results {#jdi13208-sec-0009}
=======

Clinical and laboratory characteristics of the study participants are shown in Table [1](#jdi13208-tbl-0001){ref-type="table"}. The Pro12Pro genotype was significantly higher in the albuminuria group when compared with the group without albuminuria (95.4 vs 90.4%, *P* = 0.025). Compared with the patients without albuminuria, those patients with albuminuria have a significantly high percentage of hypertension (82.2% vs 56.2%, *P* = 0.001), poor renal function (eGFR 70.6 vs 86.1 mL/min/1.73 m^2^, *P* = 0.001), higher triglyceride levels (130.0 vs 108.0 mg/dL, *P* = 0.001) and lower high‐density lipoprotein cholesterol levels (45.8 vs 48.5 mg/dL, *P* = 0.017). In addition, more patients with albuminuria receive insulin injection, take angiotensin‐converting enzyme inhibitor/angiotensin II receptor antagonist as antihypertensive treatment and use statin as lipid‐lowering drugs.

###### 

Clinical and laboratory characteristics of study patients with and without albuminuria

  Parameters                   Normoalbuminuria      Albuminuria           *P* [\*](#jdi13208-note-0003){ref-type="fn"}
  ---------------------------- --------------------- --------------------- ----------------------------------------------
  Sample size (*n*)            313                   241                   --
  Age (years)                  60.8 ± 9.9            62.6 ± 9.5            0.033
  Sex (female)                 170 (54.3%)           96 (39.8%)            0.001
  Genotype                                                                 
  Pro/Pro                      283 (90.4%)           230 (95.4%)           0.025
  Pro/Ala + Ala/Ala            30 (9.6%)             11 (4.6%)              
  Diabetes duration (years)    13.2 ± 7.5            14.3 ± 8.2            0.098
  Hypertension (%)             176 (56.2%)           198 (82.2%)           0.001
  SBP (mmHg)                   137.5 ± 17.8          140.3 ± 20.3          0.085
  DBP (mmHg)                   77.9 ± 12.3           77.9 ± 11.5           0.945
  Weight (kg)                  70.3 ± 14.0           70.3 ± 13.6           0.983
  BMI (kg/m^2^)                26.8 ± 4.5            26.7 ± 4.0            0.701
  Waist (cm)                   90.0 ± 11.1           91.7 ± 9.9            0.063
  Metabolic syndrome (%)       223 (71.2%)           194 (80.5%)           0.012
  HbA1c (%)                    7.4 ± 0.9             7.4 ± 1.1             0.284
  UACR (mg/g)                  9.4 (5.5--15.6)       105.7 (50.0--242.2)   0.001
  Serum creatinine (mg/dL)     0.8 (0.7--1.0)        1.0 (0.8--1.3)        0.001
  eGFR (mL/min/1.73 m^2^)      86.1 (71.8--99.1)     70.6 (54.4--88.5)     0.001
  Retinopathy (%)              61 (19.5%)            65 (27.0%)            0.037
  Total cholesterol (mg/dL)    167.8 ± 29            168.2 ± 33.4          0.893
  HDL (mg/dL)                  48.5 ± 12.4           45.8 ± 13.7           0.017
  LDL (mg/dL)                  89.3 ± 21.9           90.3 ± 25.7           0.653
  Triglyceride (mg/dL)         108.0 (75.0--156.0)   130.0 (86.3--188.0)   0.001
  Smoking (%)                  28 (8.9%)             26 (10.8%)            0.468
  Alcohol consumption (%)      20 (6.4%)             15 (6.2%)             0.937
  TZD (%)                      59 (18.8%)            52 (21.6%)            0.427
  Hypoglycemic treatment                                                   
  OADs (%)                     263 (84.0%)           176 (73.0%)           0.007^†^
  Insulin (%)                  6 (1.9%)              6 (2.5%)               
  Insulin + OADs (%)           42 (13.4%)            58 (24.1%)             
  Diet control (%)             2 (0.6%)              1 (0.4%)               
  Antihypertensive treatment                                               
  ACEI/ARB (%)                 139 (44.4%)           179 (74.3%)           0.001
  Lipid‐lowering drugs                                                     
  Statin (%)                   228 (72.8%)           194 (80.5%)           0.036
  Fibrate (%)                  24 (7.7%)             23 (9.5%)             0.432

Data are expressed as the mean ± standard deviation, median (interquartile range) or *n* (%).

ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor antagonist; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin A1c; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; OADs, oral antidiabetic drugs; SBP, systolic blood pressure; TZD, thiazolidinedione; UCAR, urine albumin‐to‐creatinine ratio.

*P*‐values were calculated by an unpaired Student's *t*‐test or χ^2^ analysis, or Fisher's exact test (†), sequentially.

John Wiley & Sons, Ltd

As shown in Table [2](#jdi13208-tbl-0002){ref-type="table"}, 513 (92.6%) patients were found to have the Pro12Pro (PP) genotype, 39 (7.0%) had the Pro12Ala (PA) genotype and two (0.4%) had the Ala12Ala (AA) genotype. The *Ala12* allele frequency was 4%. The Pro12Ala genotyping call rate was 100%. The distribution of Pro12Ala polymorphism in our study participants followed the Hardy--Weinberg equilibrium (*P* = 0.184). There was no significant difference in age, sex, bodyweight, diabetes duration, glycated hemoglobin A1c value, oral antidiabetic drugs, antihypertensive treatment and lipid‐lowering drugs between individuals with and without the *Ala12* allele (Table [2](#jdi13208-tbl-0002){ref-type="table"}). The Ala carriers (PA and AA) had significantly lower UACR (15.0 vs 20.5 mg/g, *P* = 0.001) and better renal function (eGFR 81.8 \[69.8--97.6\] vs 78.7 mL/min/1.73 m^2^ \[61.6--96.2\], *P* = 0.05) compared with those with the Pro12Pro genotype. The PP genotype had clearly a higher percentage of DN (44.8% vs 26.8%, *P* = 0.025), as compared with PA and AA genotypes (Figure [1](#jdi13208-fig-0001){ref-type="fig"}).

###### 

Clinical and laboratory characteristics of patients classified according to peroxisome proliferator‐activated receptor gamma Pro12Ala genotypes

  Parameters                   Pro/Pro (513)         Pro/Ala (39) + Ala/Ala (2)   *P* [\*](#jdi13208-note-0006){ref-type="fn"}
  ---------------------------- --------------------- ---------------------------- ----------------------------------------------
  Sample size (*n*)            513                   41                           --
  Age (years)                  61.6 ± 9.9            61.5 ± 7.8                   0.984
  Sex (female)                 244 (47.6%)           22 (53.7%)                   0.452
  Diabetes duration (years)    13.6 ± 7.7            14.7 ± 8.7                   0.374
  Hypertension (%)             346 (67.4%)           28 (68.3%)                   0.911
  SBP (mmHg)                   138.8 ± 18.9          137.3 ± 19.3                 0.614
  DBP (mmHg)                   78.0 ± 12.0           76.0 ± 11.0                  0.299
  Weight (kg)                  70.2 ± 13.9           71.3 ± 12.2                  0.631
  BMI (kg/m^2^)                26.7 ± 4.3            27.3 ± 4.1                   0.380
  Waist (cm)                   90.7 ± 10.6           91.4 ± 11.1                  0.671
  Metabolic syndrome (%)       388 (75.6%)           29 (70.7%)                   0.484
  HbA1c (%)                    7.4 ± 1.0             7.4 ± 0.8                    0.977
  UACR (mg/g)                  20.5 (8.5--87.4)      15.0 (4.7--54.9)             0.001
  Serum creatinine (mg/dL)     0.9 (0.7--1.1)        0.8 (0.7--1.0)               0.011
  eGFR (mL/min/1.73 m^2^)      78.7 (61.6--96.2)     81.8 (69.8--97.6)            0.05
  Retinopathy (%)              117 (22.8%)           9 (22.0%)                    0.992
  Total cholesterol (mg/dL)    168.3 ± 31.1          163.5 ± 30.0                 0.342
  HDL (mg/dL)                  47.4 ± 13.4           45.7 ± 7.6                   0.212
  LDL (mg/dL)                  90.0 ± 23.5           86.9 ± 25.4                  0.427
  Triglyceride (mg/dL)         117.0 (80.0--174.0)   109.0 (86.5--146.8)          0.404
  Smoking (%)                  53 (10.3%)            1 (2.4%)                     0.165
  Alcohol use (%)              33 (6.4%)             2 (4.9%)                     1.0
  TZD (%)                      105 (20.5%)           6 (14.6%)                    0.369
  Hypoglycemic treatment                                                          
  OADs (%)                     407 (79.3%)           32 (78.0%)                   0.329^†^
  Insulin (%)                  11 (2.1%)             1 (2.4%)                     
  Insulin + OADs (%)           93 (18.1%)            7 (17.1%)                    
  Diet control (%)             2 (0.4%)              1 (2.4%)                     
  Antihypertensive treatment                                                      
  ACEI/ARB (%)                 291 (56.7%)           27 (65.9%)                   0.255
  Lipid‐lowering drugs                                                            
  Statin (%)                   389 (75.8%)           33 (80.5%)                   0.500
  Fibrate (%)                  46 (9.0%)             1 (2.4%)                     0.239

Data are expressed as the mean ± standard deviation, median (interquartile range) or *n* (%).

ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor antagonist; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin A1c; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; OADs, oral antidiabetic drugs; SBP, systolic blood pressure; TZD, thiazolidinedione; UCAR, urine albumin‐to‐creatinine ratio.

*P*‐values were calculated by an unpaired Student's *t*‐test, chi‐squared test mark analysis or Fisher's exact test (†), sequentially.
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![Albuminuria prevalence of the peroxisome proliferator‐activated receptor gamma Pro12Ala polymorphism in type 2 diabetes patients. The peroxisome proliferator‐activated receptor gamma 2 Ala12 variant has significant protective effects against albuminuria and diabetic nephropathy. These findings suggest that genetic screening can help in the development of personalized therapies for diabetes. DN, diabetic nephropathy; No‐DN, no diabetic nephropathy.](JDI-11-923-g001){#jdi13208-fig-0001}

The distribution of *PPAR‐γ* genotypes and their relationship with DN is shown in the Table [3](#jdi13208-tbl-0003){ref-type="table"}. The frequency of genotype PP, PA and AA were 90.4%, 8.9% and 0.7% in the NA group; 94.7%, 5.3% and 0.0% in the MA group; and 98.0%, 2.0% and 0% in the MAA group, respectively. There is a linear‐by‐linear decrease in the association between (*P* = 0.012) NA, MA and MAA with *Ala* allele (Table [3](#jdi13208-tbl-0003){ref-type="table"}), suggesting that the *Ala* allele might be a protective factor that shields an individual from the presence of albuminuria.

###### 

Distribution of peroxisome proliferator‐activated receptor gamma genotypes in different categories of diabetic nephropathy

  Diabetic nephropathy   *n*   Genotype     Allele                                                    
  ---------------------- ----- ------------ ---------- --------- ------------ ------------ ---------- ----------
  Normoalbuminuria       313   283 (90.4)   28 (8.9)   2 (0.7)   0.181        594 (94.9)   32 (5.1)   0.012^†^
  Microalbuminuria       189   179 (94.7)   10 (5.3)   0 (0)     368 (97.4)   10 (2.6)                
  Macroalbuminuria       52    51 (98.0)    1 (2.0)    0 (0)     103 (99.0)   1 (1.0)                 

Data are expressed as percentages. \**P*‐values were calculated by χ^2^ analysis or the Mantel--Haenszel test for trends (†).
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To clarify the contributions of the *PPARγ Pro12Ala* gene polymorphism to the risk of albuminuria, multivariate logistic regression analyses were carried out with the possible confounders. After adjustment for univariate parameters, including age, sex, genotype, diabetes duration, hypertension, systolic blood pressure, metabolic syndrome, eGFR, retinopathy, high‐density lipoprotein, triglyceride, hypoglycemic treatment, the use of angiotensin‐converting enzyme inhibitor/angiotensin II receptor antagonist and statin, the Ala12 variant of Pro12Ala polymorphism is a significantly protective factor for albuminuria (odds ratio 0.428, 95% confidence interval 0.195--0.940, *P* = 0.034; Table [4](#jdi13208-tbl-0004){ref-type="table"}).

###### 

Logistic regression analysis for the risk of albuminuria

  Parameters               Univariate analysis    Multivariate analysis[\*](#jdi13208-note-0008){ref-type="fn"}                          
  ------------------------ ---------------------- --------------------------------------------------------------- ---------------------- -------
  PPAR‐γ (Ala12)           0.451 (0.221--0.920)   0.025                                                           0.428 (0.195－0.940)   0.034
  Age                      1.019 (1.001--1.037)   0.033                                                           --                     --
  Male sex                 1.796 (1.277--2.524)   0.001                                                           1.795 (1.169－2.757)   0.008
  Hypertension             3.584 (2.407--5.338)   0.001                                                           --                     --
  Metabolic syndrome       1.666 (1.115--2.490)   0.012                                                           --                     --
  eGFR                     0.974 (0.967--0.982)   0.001                                                           0.985 (0.976－0.994)   0.001
  Retinopathy              1.526 (1.024--2.274)   0.037                                                           1.725 (1.087－2.739)   0.021
  HDL                      0.983 (0.969--0.997)   0.017                                                           --                     --
  Triglyceride             1.004 (1.002--1.007)   \<0.001                                                         1.003 (1.000－1.006)   0.040
  Hypoglycemic treatment   1.395 (1.128--1.724)   0.007                                                           1.348 (1.049－1.732)   0.020
  ACEI/ARB use             3.614 (2.509--5.205)   \<0.001                                                         2.554 (1.331－4.900)   0.005
  Statin use               0.650 (0.434--0.974)   0.036                                                           --                     --

Adjusted for age, sex, genotype, diabetes duration, hypertension, systolic blood pressure (SBP), waist, metabolic syndrome, estimated glomerular filtration rate (eGFR), retinopathy, high‐density lipoprotein (HDL), triglyceride, hypoglycemic treatment, the use of angiotensin‐converting enzyme inhibitor (ACEI)/angiotensin II receptor antagonist (ARB) and statin.
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Discussion {#jdi13208-sec-0010}
==========

The present study demonstrated that the *Ala12* variant of the Pro12Ala polymorphism of the *PPARγ2* gene showed significant risk reduction with albuminuria after adjustments were made for the related risk factors. The *Pro12* allele is significantly associated with higher serum creatinine and UACR levels. In Caucasian populations[9](#jdi13208-bib-0009){ref-type="ref"}, [16](#jdi13208-bib-0016){ref-type="ref"}, [17](#jdi13208-bib-0017){ref-type="ref"}, the *Ala12* allele had shown a protective effect against worsening albuminuria and DN. However, the protective role of the Pro12Ala polymorphism is not consistent in Asian studies, and Mori *et al*.[8](#jdi13208-bib-0008){ref-type="ref"} reported no significant difference in nephropathy prevalence between PP and PA + AA genotypes among the Japanese population. The present results are in agreement with the results from Li *et al*.[10](#jdi13208-bib-0010){ref-type="ref"} and Liu *et al*.[13](#jdi13208-bib-0013){ref-type="ref"}, which reported the Ala12 variant significantly protects against DN in a central Han cluster of Chinese patients[25](#jdi13208-bib-0025){ref-type="ref"}. To the best of our knowledge, this is the first report of Pro12Ala polymorphism significantly related to a reduced risk of albuminuria for type 2 diabetes mellitus patients in Taiwan, mostly of southern Han Chinese ancestry[26](#jdi13208-bib-0026){ref-type="ref"}.

The first evidence for the connection between the Pro12Ala polymorphism in the *PPARγ* gene and improving insulin sensitivity was reported by Deeb *et al.* [15](#jdi13208-bib-0015){ref-type="ref"} Furthermore, gene knockout mouse models confirmed that *PPARγ* plays an important role in regulating insulin sensitivity[27](#jdi13208-bib-0027){ref-type="ref"}, which might be connected to the pathogenesis of albuminuria[28](#jdi13208-bib-0028){ref-type="ref"}. Currently, it is recognized that the Pro12Ala polymorphism plays an important role in the risk reduction of albuminuria in patients with type 2 diabetes mellitus [9](#jdi13208-bib-0009){ref-type="ref"}, [10](#jdi13208-bib-0010){ref-type="ref"}, [13](#jdi13208-bib-0013){ref-type="ref"}, [14](#jdi13208-bib-0014){ref-type="ref"}, [16](#jdi13208-bib-0016){ref-type="ref"}, [17](#jdi13208-bib-0017){ref-type="ref"}, [18](#jdi13208-bib-0018){ref-type="ref"}, [19](#jdi13208-bib-0019){ref-type="ref"}. In addition, the *Ala12* allele showed enhanced resistance of oxidative stress[29](#jdi13208-bib-0029){ref-type="ref"}. Oxidative stress is associated with hyperglycemia, insulin resistance and DN[30](#jdi13208-bib-0030){ref-type="ref"}. Thus, the Pro12Ala polymorphism might alleviate DN through the mechanism of improving insulin sensitivity and increasing resistance of oxidative stress.

The United Kingdom Prospective Diabetes Study revealed that independent risk factors for the development of albuminuria were male sex, increased waist circumference, triglyceride, low‐density lipoprotein, glycated hemoglobin A1c, smoking and previous retinopathy[31](#jdi13208-bib-0031){ref-type="ref"}. Some studies have shown an association between albuminuria and hypertension[32](#jdi13208-bib-0032){ref-type="ref"}, [33](#jdi13208-bib-0033){ref-type="ref"}. In the present study, individuals with albuminuria are significantly associated with male sex, triglyceride and retinopathy, but not with higher waist circumference, low‐density lipoprotein, glycated hemoglobin A1c and hypertension after adjustment for confounders. Furthermore, the *Pro12* allele is an additional risk factor.

A meta‐analysis showed the *Ala* carriers have a lower chance of developing diabetic retinopathy among Caucasian type 2 diabetes mellitus patients, but not among Asian patients[18](#jdi13208-bib-0018){ref-type="ref"}. The ethnic differences might be related to the fact that the *Ala* allele is detected more often in Caucasians (14%), but is relatively lower in Asians (4% of Japanese and 4% of Chinese)[8](#jdi13208-bib-0008){ref-type="ref"}, [9](#jdi13208-bib-0009){ref-type="ref"}, [10](#jdi13208-bib-0010){ref-type="ref"}, [11](#jdi13208-bib-0011){ref-type="ref"}, [12](#jdi13208-bib-0012){ref-type="ref"}, [13](#jdi13208-bib-0013){ref-type="ref"}, [14](#jdi13208-bib-0014){ref-type="ref"}. The present study shows that the *Ala* carriers also are less likely to develop diabetic retinopathy compared with the *Pro12Pro* genotype, but is not statistically significant, partly due to the low frequency of *Ala* carriers in the present series. As a complex disease, diabetic retinopathy is a complication involving polygenic and environmental factors, and the contributing factor of the Pro12Ala polymorphism in the *PPARγ2* gene should require further studies to elucidate its role.

However, there were several limitations to the present study. First, this study was a case--control study; therefore, it could not explore causal relationships between the risk factors and the development of albuminuria and DM nephropathy. Second, those patients with ESRD were excluded from the study for anuria. Therefore, we could not survey the relationship between the polymorphism and ESRD risk.

In conclusion, the present study shows that the *PPAR‐γ2* *Ala12* variant is related to risk reduction of albuminuria among patients with type 2 diabetes mellitus. Further studies are still required to elucidate the role of this polymorphism for predicting and treating kidney dysfunction in type 2 diabetes mellitus.
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